BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22955911)

  • 1. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
    Davids MS; Deng J; Wiestner A; Lannutti BJ; Wang L; Wu CJ; Wilson WH; Brown JR; Letai A
    Blood; 2012 Oct; 120(17):3501-9. PubMed ID: 22955911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
    Fiorcari S; Brown WS; McIntyre BW; Estrov Z; Maffei R; O'Brien S; Sivina M; Hoellenriegel J; Wierda WG; Keating MJ; Ding W; Kay NE; Lannutti BJ; Marasca R; Burger JA
    PLoS One; 2013; 8(12):e83830. PubMed ID: 24376763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
    Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
    Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
    Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
    Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
    Chapman CM; Sun X; Roschewski M; Aue G; Farooqui M; Stennett L; Gibellini F; Arthur D; Pérez-Galán P; Wiestner A
    Clin Cancer Res; 2012 Apr; 18(7):1979-91. PubMed ID: 22351695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
    Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
    Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
    Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
    Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma.
    Plander M; Ugocsai P; Seegers S; Orsó E; Reichle A; Schmitz G; Hofstädter F; Brockhoff G
    Ann Hematol; 2011 Dec; 90(12):1381-90. PubMed ID: 21465189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.
    Pedersen IM; Kitada S; Leoni LM; Zapata JM; Karras JG; Tsukada N; Kipps TJ; Choi YS; Bennett F; Reed JC
    Blood; 2002 Sep; 100(5):1795-801. PubMed ID: 12176902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells.
    Vangapandu HV; Ayres ML; Bristow CA; Wierda WG; Keating MJ; Balakrishnan K; Stellrecht CM; Gandhi V
    Neoplasia; 2017 Oct; 19(10):762-771. PubMed ID: 28863345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro.
    Bäckman E; Bergh AC; Lagerdahl I; Rydberg B; Sundström C; Tobin G; Rosenquist R; Linderholm M; Rosén A
    Haematologica; 2007 Nov; 92(11):1495-504. PubMed ID: 18024398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
    Paiva C; Godbersen JC; Soderquist RS; Rowland T; Kilmarx S; Spurgeon SE; Brown JR; Srinivasa SP; Danilov AV
    PLoS One; 2015; 10(11):e0143685. PubMed ID: 26606677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-selectin controls trafficking of chronic lymphocytic leukemia cells in lymph node high endothelial venules in vivo.
    Lafouresse F; Bellard E; Laurent C; Moussion C; Fournié JJ; Ysebaert L; Girard JP
    Blood; 2015 Sep; 126(11):1336-45. PubMed ID: 26162407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.